Stocks Telegraph

KPTI Stock Price History and Quote Analysis: Insights for Investors

NASDAQ:KPTI

Karyopharm Therapeutics Inc.

$0.86
0.0142+1.68%
At Close 4:00 PM
$0.88
0.02+2.32%
After-Market 06:52 PM
59.36
BESG ScoreESG Rating

KPTI FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

KPTI Income Statement


A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
revenue42.786M33.126M33.747M36.009M37.579M
cost of revenue1.556M1.996M1.563M911.00K1.194M
gross profit41.23M31.13M32.184M35.098M36.385M
gross profit ratio0.9640.940.9540.9750.968
research and development expenses38.28M35.34M39.304M35.553M31.477M
general and administrative expenses31.07M29.549M30.688M30.805M34.481M
selling and marketing expenses00000
selling general and administrative expenses31.07M29.549M30.688M30.805M34.481M
other expenses14.296M196.00K-211.00K89.00K30.00K
operating expenses69.35M64.889M69.992M66.358M65.958M
cost and expenses70.906M66.885M71.555M67.269M67.152M
interest income1.93M2.156M2.52M2.75M2.824M
interest expense8.949M5.884M6.208M6.073M5.784M
depreciation and amortization91.00K85.00K77.00K2.839M83.00K
ebitda-28.029M-33.674M-37.731M-28.421M-26.636M
ebitda ratio-0.655-1.017-1.118-0.789-0.709
operating income-28.12M-33.759M-37.808M-31.26M-29.573M
operating income ratio-0.657-1.019-1.12-0.868-0.787
total other income expenses net51.979M-3.532M-3.899M89.00K30.00K
income before tax23.859M-37.291M-41.707M-34.494M-32.503M
income before tax ratio0.558-1.126-1.236-0.958-0.865
income tax expense67.00K71.00K130.00K12.00K127.00K
net income23.792M-37.362M-41.837M-34.506M-32.63M
net income ratio0.556-1.128-1.24-0.958-0.868
eps0.20-0.32-0.36-0.30-0.29
eps diluted-0.20-0.32-0.36-0.30-0.29
weighted average shs out121.027M115.454M114.778M114.401M114.207M
weighted average shs out dil154.425M115.454M114.778M114.401M114.207M
Graph

KPTI Balance Sheet


Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
cash and cash equivalents84.806M31.087M52.891M43.655M80.894M
short term investments67.35M117.95M139.212M164.66M155.871M
cash and short term investments152.156M149.037M192.103M208.315M236.765M
net receivables37.995M31.082M26.962M37.923M32.28M
inventory3.476M2.769M3.043M3.105M3.672M
other current assets14.913M15.478M11.813M178.539M18.097M
total current assets208.54M198.366M233.921M247.164M291.381M
property plant equipment net3.799M4.454M4.882M5.482M6.062M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments304.00K304.00K301.00K381.00K387.00K
tax assets00000
other non current assets1.334M1.334M1.334M16.933M0
total non current assets5.437M6.092M6.517M22.796M6.449M
other assets01.001.0000
total assets213.977M204.458M240.438M269.96M297.83M
account payables2.797M5.028M3.123M943.00K2.287M
short term debt3.545M3.425M3.308M3.195M3.084M
tax payables00000
deferred revenue0-1.000051.808M
other current liabilities51.277M56.888M63.048M57.941M1.749M
total current liabilities57.619M65.341M69.479M62.079M58.928M
long term debt191.131M171.127M170.919M170.702M174.997M
deferred revenue non current73.499M132.479M132.479M132.479M132.718M
deferred tax liabilities non current955.00K1.884M2.789M-132.479M-132.718M
other non current liabilities22.913M2.582M978.00K199.654M135.153M
total non current liabilities288.498M308.072M307.165M370.356M310.15M
other liabilities01.000-62.079M0
capital lease obligations955.00K1.884M2.789M6.863M7.584M
total liabilities346.117M373.413M376.644M370.356M369.078M
preferred stock00000
common stock13.00K12.00K12.00K12.00K12.00K
retained earnings-1.501B-1.524B-1.487B-1.445B-1.411B
accumulated other comprehensive income loss-605.00K-518.00K-161.00K-742.00K-783.00K
other total stockholders equity1.369B1.356B1.351B1.346B1.34B
total stockholders equity-132.14M-168.955M-136.206M-100.396M-71.248M
total equity-132.14M-168.955M-136.206M-100.396M-71.248M
total liabilities and stockholders equity213.977M204.458M240.438M269.96M297.83M
minority interest00000
total investments67.654M118.254M139.513M164.66M155.871M
total debt195.631M176.436M177.016M170.702M178.081M
net debt110.825M145.349M124.125M127.047M97.187M
Graph

KPTI Cash Flow


A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
deferred income tax007.867M-936.00K-1.015M
stock based compensation5.41M4.97M5.182M5.078M6.06M
change in working capital-9.474M-10.715M18.794M549.00K1.614M
accounts receivables-6.913M-4.12M10.961M-5.643M2.92M
inventory-707.00K274.00K62.00K567.00K155.00K
accounts payables-2.231M1.905M2.18M-1.344M-6.758M
other working capital377.00K-8.774M5.591M6.969M5.297M
other non cash items-42.874M6.378M-8.668M205.00K190.00K
net cash provided by operating activities-38.498M-43.725M-18.585M-29.53M-25.698M
investments in property plant and equipment0-195.00K000
acquisitions net00000
purchases of investments-4.903M-31.608M-16.56M-46.065M-36.194M
sales maturities of investments56.165M53.743M43.403M38.38M57.364M
other investing activites51.262M22.135M-1.0000
net cash used for investing activites51.262M21.94M26.843M-7.685M21.17M
debt repayment-40.194M0000
common stock issued772.00K0264.00K0860.00K
common stock repurchased00000
dividends paid00000
other financing activites40.966M000860.00K
net cash used provided by financing activities40.966M0264.00K38.565M860.00K
effect of forex changes on cash-11.00K-16.00K89.00K-52.00K-26.00K
net change in cash53.719M-21.804M8.691M-37.267M-3.694M
cash at end of period84.806M31.087M52.891M44.581M81.848M
cash at beginning of period31.087M52.891M44.20M81.848M85.542M
operating cashflow-38.498M-43.725M-18.585M-29.53M-25.698M
capital expenditure0-195.00K000
free cash flow-38.498M-43.92M-18.585M-29.53M-25.698M
Graph

Frequently Asked Questions

How did Karyopharm Therapeutics Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, KPTI generated $42.79M in revenue last quarter, while its costs came in at $1.56M.

Last quarter, how much Gross Profit did Karyopharm Therapeutics Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Karyopharm Therapeutics Inc. reported a $41.23M Gross Profit for the quarter ended Jun 30, 2024.

Have KPTI's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. KPTI incurred $69.35M worth of Operating Expenses, while it generated -$28.12M worth of Operating Income.

How much Net Income has KPTI posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Karyopharm Therapeutics Inc., the company generated $23.79M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Karyopharm Therapeutics Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Karyopharm Therapeutics Inc. as of the end of the last quarter was $84.81M.

What are KPTI's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, KPTI had Total Net Receivables of $38.00M.

In terms of Total Assets and Current Assets, where did Karyopharm Therapeutics Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of KPTI were $208.54M, while the Total Assets stand at $213.98M.

As of the last quarter, how much Total Debt did Karyopharm Therapeutics Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of KPTI's debt was $195.63M at the end of the last quarter.

What were KPTI's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, KPTI reported total liabilities of $346.12M.

How much did KPTI's Working Capital change over the last quarter?

Working Capital Change for KPTI was -$9.47M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

KPTI generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. KPTI generated -$38.50M of Cash from Operating Activities during its recently reported quarter.

What was KPTI's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. KPTI reported a $53.72M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph